Evidence map›Paper›PMID 41257905›Full record

ArticleScientific reports2025

Proof of concept for the usability of the IRRAMICE for proton preclinical radiobiological research by a traceable dosimetry evaluation.

Reem Ahmad, Richard Coos, Ileana Silvestre Patallo, Colin Baker, Christian Brunet, Nilsu Cini, Andrew Gosling, Alex Grimwood, Mohammad Hussein, Stephane Lucas and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Reem Ahmad *Department of Medical Physics and Biomedical Engineering, University College London, London, UK. r.h.ahmad@ucl.ac.uk.ORCID http://orcid.org/0000-0001-5529-9802
Richard Coos *LARN-NARILIS, University of Namur, Namur, Belgium. richard.coos@unamur.be.ORCID http://orcid.org/0009-0008-9266-0802
Ileana Silvestre Patallo *Radiotherapy and Radiation Dosimetry Group, National Physical Laboratory, Teddington, UK. ileana.silvestre.patallo@npl.co.uk.ORCID http://orcid.org/0000-0003-0467-3870
Colin BakerMedical Physics Department, Proton Therapy Centre, University College Hospital, London, UK.
Christian BrunetMedical Physics Department, Proton Therapy Centre, University College Hospital, London, UK.
Nilsu CiniResearch Unit For Analysis By Nuclear Reaction, University of Namur, Namur, Belgium.ORCID http://orcid.org/0000-0001-6370-6535
Andrew GoslingMedical Physics Department, Proton Therapy Centre, University College Hospital, London, UK.
Alex GrimwoodMedical Physics Department, Proton Therapy Centre, University College Hospital, London, UK.
Mohammad HusseinRadiotherapy and Radiation Dosimetry Group, National Physical Laboratory, Teddington, UK.
Stephane LucasLARN-NARILIS, University of Namur, Namur, Belgium.
Andrew NisbetDepartment of Medical Physics and Biomedical Engineering, University College London, London, UK.
Hugo PalmansRadiotherapy and Radiation Dosimetry Group, National Physical Laboratory, Teddington, UK.ORCID http://orcid.org/0000-0002-0235-5118
Andrew PoynterDepartment of Medical Physics and Biomedical Engineering, University College London, London, UK.
Alison WarryMedical Physics Department, Proton Therapy Centre, University College Hospital, London, UK.
Maria HawkinsDepartment of Medical Physics and Biomedical Engineering, University College London, London, UK.

Funding

PROTHERWAL C7289Radiation Research Unit at the Cancer Research UK City of London Centre Award C7893/A28990
6 · The paper itself

Abstract

Radiobiology relies on animal studies to demonstrate efficacy and safety of treatments. For proton-based studies in clinical settings, bespoke solutions, enabling animal irradiations without compromising health and safety regulations, need to be developed to facilitate the research. This study aims to demonstrate the usability of the IRRAMICE, a novel system with bespoke collimators to effectively treat small targets, within proton clinical facilities. Following a clinical workflow of planning CT, treatment plan design and delivery, a dosimetric evaluation of the IRRAMICE was conducted. Traceable absorbed dose was determined by measurements with (i) ion chamber, (ii) alanine pellets within a mouse phantom and a bespoke holder in the IRRAMICE, and (iii) Gafchromic film in the holder for a relative evaluation of the collimation system. Dose determined with alanine pellets in the mouse phantom were within 2% of the planned dose. The 2%/2 mm local gamma analysis of the dose distribution of the collimated beam spot determined by the film and the treatment planning system showed an average 98.3% passing rate. Through measurements in mouse phantoms, IRRAMICE demonstrated to be a suitable device for enabling the setup and delivery of treatment plans in a reliable and reproducible manner, to facilitate in vivo preclinical experiments.

Indexed as

Proton TherapyRadiobiologyRadiometryAnimalsMicePhantoms, ImagingProof of Concept StudyRadiotherapy DosageRadiotherapy Planning, Computer-AssistedDosimetryIRRAMICEPreclinicalProton therapy

Identifiers

PMID41257905
PMCPMC12630642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.